Novo Nordisk A/S $NVO Stock Position Cut by Union Bancaire Privee UBP SA

Union Bancaire Privee UBP SA decreased its stake in shares of Novo Nordisk A/S (NYSE:NVO) by 47.8% during the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 14,930 shares of the company’s stock after selling 13,660 shares during the period. Union Bancaire Privee UBP SA’s holdings in Novo Nordisk A/S were worth $549,000 as of its most recent SEC filing.

Other institutional investors also recently made changes to their positions in the company. Revolve Wealth Partners LLC lifted its position in Novo Nordisk A/S by 8.7% in the fourth quarter. Revolve Wealth Partners LLC now owns 2,490 shares of the company’s stock worth $214,000 after purchasing an additional 200 shares during the period. AQR Capital Management LLC raised its stake in shares of Novo Nordisk A/S by 21.0% in the 1st quarter. AQR Capital Management LLC now owns 62,099 shares of the company’s stock worth $4,312,000 after buying an additional 10,758 shares in the last quarter. Sivia Capital Partners LLC raised its stake in shares of Novo Nordisk A/S by 18.2% in the 2nd quarter. Sivia Capital Partners LLC now owns 10,320 shares of the company’s stock worth $712,000 after buying an additional 1,587 shares in the last quarter. Invesco Ltd. lifted its holdings in shares of Novo Nordisk A/S by 26.3% in the second quarter. Invesco Ltd. now owns 419,691 shares of the company’s stock valued at $28,967,000 after buying an additional 87,467 shares during the period. Finally, Gamco Investors INC. ET AL bought a new position in Novo Nordisk A/S during the second quarter valued at about $314,000. 11.54% of the stock is owned by institutional investors and hedge funds.

Novo Nordisk A/S Trading Down 0.1%

NYSE:NVO opened at $48.01 on Monday. The stock has a fifty day simple moving average of $43.79 and a 200 day simple moving average of $45.82. The firm has a market capitalization of $214.36 billion, a price-to-earnings ratio of 11.27, a price-to-earnings-growth ratio of 4.33 and a beta of 0.78. Novo Nordisk A/S has a 1-year low of $35.12 and a 1-year high of $71.79. The company has a quick ratio of 0.56, a current ratio of 0.79 and a debt-to-equity ratio of 0.59.

Novo Nordisk A/S (NYSE:NVO) last posted its quarterly earnings data on Tuesday, March 31st. The company reported $1.03 EPS for the quarter. Novo Nordisk A/S had a net margin of 37.23% and a return on equity of 63.31%. The company had revenue of $10.85 billion during the quarter. Sell-side analysts forecast that Novo Nordisk A/S will post 3.42 earnings per share for the current year.

Analysts Set New Price Targets

NVO has been the topic of several research reports. TD Cowen cut shares of Novo Nordisk A/S from a “buy” rating to a “hold” rating and set a $42.00 price target on the stock. in a research report on Tuesday, March 10th. Morgan Stanley raised shares of Novo Nordisk A/S from an “underweight” rating to an “equal weight” rating and set a $40.00 price objective on the stock in a research note on Tuesday, March 3rd. Wall Street Zen downgraded shares of Novo Nordisk A/S from a “buy” rating to a “hold” rating in a report on Saturday, June 20th. Nordea Equity Research raised shares of Novo Nordisk A/S from a “hold” rating to a “buy” rating in a research note on Friday, June 19th. Finally, Wolfe Research started coverage on shares of Novo Nordisk A/S in a research report on Thursday, March 26th. They issued a “peer perform” rating on the stock. Five research analysts have rated the stock with a Buy rating, seventeen have given a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of “Hold” and a consensus target price of $65.56.

About Novo Nordisk A/S

Novo Nordisk A/S is a Danish multinational pharmaceutical company headquartered in Bagsværd, Denmark, best known for its leadership in diabetes care and metabolic health. The company traces its roots to early Danish insulin production in the 1920s and was established in its current form through a 1989 merger of predecessor companies. Novo Nordisk develops, manufactures and markets pharmaceutical products and devices that address chronic and serious diseases, with a strong emphasis on long-term treatment and patient support.

The company’s core product portfolio centers on diabetes therapies, including a range of insulins and modern incretin-based treatments.